Press Releases

Date Title and Summary Additional Formats
Toggle Summary Radius Health Business Update
Growth of 14% for new U.S. TYMLOS® patients in Q1, 2021 vs. Q4, 2020 Q1, 2021 TYMLOS net revenue impacted by seasonality and distribution channel destocking April, 2021 month-to-date new patient adds indicate significant patient growth Three pivotal studies: all remain on track for 2H, 2021
View HTML
Toggle Summary Radius Health to Announce First Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Friday, May 7, 2021
BOSTON , April 20, 2021 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its first quarter financial results on Friday, May 7, 2021 . The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and provide a
View HTML
Toggle Summary Radius Health Provides Update on Abaloparatide
Regulatory success achieved in Japan by partner Teijin Pharma Limited Ostabaro® approved for treatment of male & female OP patients at high risk of fracture Japan is currently the largest anabolic market in the world $10 million milestone to be generated from Japan approval EU: intend to re-file
View HTML
Toggle Summary Radius Health, Inc. Announces $175 Million Financing Transaction
Repurchases $112.2 million of principal amount of the 3.00% convertible notes due September 1, 2024 (“2024 Notes”), representing approximately 37% of the outstanding 2024 Notes Estimated excess cash proceeds of approximately $14.2 million will be added to the balance sheet Eliminates approximately
View HTML
Toggle Summary Radius Health, Inc.: Fourth Quarter and Full Year Results
Full year 2020 TYMLOS® U.S. net sales of $208 million was year-over-year growth of 20% Q4 2020 TYMLOS U.S. net sales: $60 million was 8% growth vs. Q4 2019 and 19% growth vs. Q3 2020 New patient starts: increased by 26% in Q4 2020 vs. Q3 2020 ATOM, wearABLe and EMERALD studies: on schedule for 2H
View HTML
Toggle Summary Radius Health to Present at 10th Annual SVB Leerink Global Healthcare Conference
BOSTON , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that it will provide a corporate update at the 10 th Annual SVB Leerink Global Healthcare Conference at 10:40 a.m. ET on Thursday, February 25, 2021 . A live webcast of the presentation will be available
View HTML
Toggle Summary Radius Health to Announce Fourth Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Thursday, February 25, 2021
BOSTON , Feb. 16, 2021 (GLOBE NEWSWIRE) -- Radius Health  (Nasdaq: RDUS) announced today that it will release its fourth quarter financial results on Thursday, February 25, 2021. The Company will host a conference call and live audio webcast at 8:30 a.m.
View HTML
Toggle Summary Radius Health, Inc. Provides Abaloparatide Business Update
17% growth in January 2021 for new TYMLOS® patients vs. previous 4 month trailing average Histomorphometry study published: Journal of Bone & Mineral Research in   January 2021 Cardiovascular safety study published: Journal of Clinical Endocrinology & Metabolism in November 2020 Japan : with our
View HTML
Toggle Summary Radius Health to Present at the 39th Annual J.P. Morgan Healthcare Conference
BOSTON , Jan. 06, 2021 (GLOBE NEWSWIRE) -- Radius Health , Inc. (Nasdaq: RDUS), today announced that Kelly Martin, President and CEO will present a virtual corporate update at the 39 th  Annual J.P. Morgan Healthcare Conference on Wednesday, January 13 at 9:10 a.m. EST .
View HTML
Toggle Summary Radius Health, Inc. Announces Acquisition of Orphan Disease Program
RAD011 is a pivotal-trial ready synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases Prader-Willi syndrome (“PWS”) will be the initial indication, which has been granted Orphan Drug and Fast Track Designation by the FDA Acquisition and
View HTML